Immunotherapy for Non-melanoma Skin Cancer
Immunotherapy for non-melanoma skin cancer" will use real-world cases to discuss the role of immunotherapy in the treatment of non-melanoma skin cancer. The webinar will include a summary of data for immunotherapy for non-melanoma skin cancers as well as a discussion of adverse events.
At the conclusion of this activity, participants should be able to:
- Define non-melanoma skin cancers that oculd benefit from immunotherapy.
- Summarize available immunotherapies for non-melanoma skin cancers.
- Discuss outcomes and adverse events associated with immunotherapy for non-melanoma skin cancers.
Emily Ruiz, MD, MPH
Dr. Ruiz is a board-certified dermatologist and the Director of the Mohs and Dermatologic Surgery Center, as well as the Director of Mohs Surgery at the VA Boston Healthcare System. She is also an Assistant Professor at Harvard Medical School.
Abigail Waldman, MD, MHS
Dr. Waldman is a board-certified dermatologist and the Academic Director of the Mohs and Dermatologic Surgery Center, as well as the Director of the High-Risk Skin Cancer Clinic at the Dana-Farber Brigham Cancer Center. She is also an Assistant Professor at Hardvard medical School.
CME: 1.00 AMA PRA Category 1 Credit™
The American Society for Dermatologic Surgery (ASDS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASDS designates this activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Copyright 2022 American Society for Dermatologic Surgery (ASDS). All Rights Reserved.